Patients perspectives on adjuvant therapy in renal cell carcinoma.

被引：3
|
作者：
Battle, Dena
Jonasch, Eric
Hammers, Hans J.
Derweesh, Ithaar
George, Daniel J.
Bex, Axel
Ljungberg, Borje
Staehler, Michael D.
机构：
[1] KCCure, Alexandria, VA USA
[2] UT MD Anderson Canc Ctr, Houston, TX USA
[3] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA
[4] Univ Calif San Diego, San Diego, CA USA
[5] Duke Univ, Duke Canc Inst, Durham, NC USA
[6] Netherlands Canc Ctr, Amsterdam, Netherlands
[7] Umea Univ, Umea, Sweden
[8] Ludwig Maximilians Univ Munchen, Univ Hosp Munich Grosshadern, Munich, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 06期
关键词：
D O I：
10.1200/JCO.2018.36.6_suppl.644
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
644
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Anxiety and patients: Perspectives on surveillance and adjuvant therapy in renal cell carcinoma.
    Battle, Dena
    Hammers, Hans J.
    Jonasch, Eric
    Derweesh, Ithaar
    George, Daniel J.
    Bex, Axel
    Ljungberg, Borje
    Staehler, Michael D.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [2] PATIENTS PERSPECTIVES ON ADJUVANT THERAPY IN RENAL CELL CARCINOMA
    Battle, Dena
    Hammers, Hans
    Jonasch, Eric
    Derweesh, Ithaar
    George, Daniel
    Ljungberg, Borje
    Bex, Axel
    Staehler, Michael
    JOURNAL OF UROLOGY, 2018, 199 (04): : E875 - E875
  • [3] Adjuvant therapy for renal cell carcinoma. Relevant patient and tumor factors
    Bedke, Jens
    Gruenwald, Viktor
    UROLOGIE, 2024, 63 (12): : 1224 - 1231
  • [4] Patient perceptions of benefits and risks of adjuvant therapy in renal cell carcinoma.
    Battle, Dena
    Msaouel, Pavlos
    Pal, Sumanta Monty
    Vaishampayan, Ulka N.
    Staehler, Michael D.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [5] Adjuvant therapy in renal cell carcinoma: Current knowledges and future perspectives
    Larroquette, Mathieu
    Peyraud, Florent
    Domblides, Charlotte
    Lefort, Felix
    Bernhard, Jean-Christophe
    Ravaud, Alain
    Gross-Goupil, Marine
    CANCER TREATMENT REVIEWS, 2021, 97
  • [6] Pharmacodynamic study of antiangiogenic therapy in patients with renal cell carcinoma.
    Anandappa, G.
    Sala, E.
    Cheow, H. K.
    Bird, N. J.
    Shaw, A.
    Priest, A. N.
    Gill, A.
    Fryer, T.
    Hong, Y. T.
    Smith, R.
    Backen, A.
    Whitcher, B.
    Jonson, A.
    Richards, D.
    Cookson, L.
    Lee, W. M. F.
    Dive, C.
    Fife, K. M.
    Jodrell, D. I.
    Eisen, T.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [7] Adjuvant surgery following biological response modifier therapy extends survival in patients with metastatic renal cell carcinoma.
    Krishnamurthi, V
    Novick, AC
    Bukowski, R
    JOURNAL OF UROLOGY, 1998, 159 (05): : 198 - 198
  • [8] Adjuvant therapy for renal cell carcinoma
    Naomi B. Haas
    Robert Uzzo
    Current Oncology Reports, 2008, 10 : 245 - 252
  • [9] Adjuvant therapy for renal cell carcinoma
    Jacobsohn, Kenneth M.
    Wood, Christopher G.
    SEMINARS IN ONCOLOGY, 2006, 33 (05) : 576 - 582
  • [10] Adjuvant Therapy for Renal Cell Carcinoma
    Pinto, Alvaro
    CLINICAL GENITOURINARY CANCER, 2014, 12 (06) : 408 - 412
12345